Clinical Trials Logo

Hashimoto clinical trials

View clinical trials related to Hashimoto.

Filter by:
  • None
  • Page 1

NCT ID: NCT06112340 Recruiting - Eye Diseases Clinical Trials

A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Start date: October 11, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

NCT ID: NCT05276063 Recruiting - Eye Diseases Clinical Trials

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

LIDS
Start date: July 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

NCT ID: NCT04472988 Completed - Hashimoto Clinical Trials

Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether Eye Movement Desensitization and Reprocessing (EMDR) is effective in decreasing the level of autoantibodies of patients with autoimmune thyroiditis. The investigators hypothesize that processing traumatic memories from events that happened before the illness onset will have a positive impact first on the psyche (a) by decreasing the level of dissociation, alexithymia, anger, and (b) by increasing the quality of life and emotional regulation, than those in the control group. Secondly, it will have an impact on the biological level, by decreasing the level of autoantibodies, antithyroglobulin antibody (anti-Tg) and anti-thyroid peroxidase antibody (anti-TPO), which are the main antibodies detected in chronic autoimmune thyroiditis.